D&O Insurance Explained: Side A/B/C Coverage and What Securities Claims Cost

Directors and officers (D&O) insurance protects corporate directors and officers against personal liability for claims arising from their managerial decisions, and reimburses the company for the indemnification it owes them. The standard structure is a three-part tower: Side A pays protected persons directly where the company cannot or will not indemnify (insolvency is the classic case); Side B reimburses the company for indemnification it pays; Side C — entity coverage — pays the company's own liability in securities claims, typically with a shared limit that the company's losses erode first. Around the tower sit retentions (D&O's deductibles), exclusions and, increasingly, severe market pressure on price and terms that followed the 2020-2023 litigation spikes.

USA Post publishes information about insurance structures, not coverage advice. Policy terms control; review placements with a broker.

Why is Side A the most important layer?

Because it answers the worst scenarios. If a company becomes insolvent — bankruptcy triggers a flood of claims while the estate's assets, and the company's ability to indemnify, disappear — Side A still pays the individuals, without retention and without erosion by entity losses. The same protection matters for claims the company is legally barred from indemnifying: under Delaware Section 145 and most statutes, a company cannot indemnify a director for a final judgment of breach of fiduciary duty or certain settlements — and derivative settlements often structure non-indemnifiable payments. Insurance-industry practice prices this: standalone Side A excess layers, dropping down over eroded primary towers, became the fastest-growing D&O product of the 2020s, precisely because the entity's coverage erodes fast in a big securities action while the individuals' need never goes away.

What do the major exclusions do?

Six dominate negotiations. The insured-versus-insured exclusion bars claims by the company against its own directors — preventing collusive suits — with carve-backs for derivative claims that independent committee members pursue. The fraud or final adjudication exclusion applies where the underlying facts are finally adjudicated as fraudulent or criminal conduct, so the insurer pays defense costs until adjudication and reclaims if fraud is finally determined (as occurred in several post-Theranos-style biodistrict cases). The securities-claims aggregate caps Side C at a sublimit in many primary policies. The professional-services exclusion keeps E&O risks out. The pollution and bodily-injury exclusions carve classic property exposures to other lines. And conduct exclusions for known pending litigation and specific fact patterns are negotiated at placement — SPAC sponsors and companies with pending investigations often buy with conduct exclusions naming them.

What drove the 2020-2023 market crisis and where are prices now?

A collision of loss trends: SPAC-litigation and IPO-wave securities suits, event-driven litigation (opioids, chemicals, data breaches — each generating D&O theories), #MeToo governance claims, and Delaware merger rulings that made process failures costly. Primary rates rose double digits for several years; capacity from new MGAs flooded the excess layers, then retreated; Side A standalone stayed the steadiest product. By 2024-2025 the market re-stabilized with risk-adjusted pricing: public-company primary rates fell modestly from peak, while IPO and SPAC pricing remained elevated versus pre-2020. The structural lessons persisted: disclosure-period scrutiny of the public D&O tower before an IPO (the "tail" covering the offering), run-off towers for acquired companies, and bankruptcy-triggered demand.

What do securities claims actually cost a tower?

Defense costs, mostly. A decade of NERA Cornerstone-type data places median securities class action settlements in the tens of millions with the tail long — mega-settlements in the hundreds of millions and a handful above a billion; defense costs add 20-35 percent on top. A $10 million primary tower erodes in the early pleading stage of a large case, which is why public companies buy $50-200 million towers. Derivative and merger objections cost less per case but come in volume — the Delaware docket's process claims settle for governance reforms plus fees, with insurers funding defense throughout. Regulatory investigations — SEC subpoenas and enforcement — increasingly consume tower capacity even where no private suit follows, a coverage-development trend of the 2020s: policies now define and often sublimit regulatory-defense coverage explicitly.

How should a board evaluate its program?

1. Match tower size to litigation exposure: market cap, deal pipeline, cyber and ESG litigation surfaces, and bankruptcy risk (which turns Side A into the only layer).
2. Stress-test erosion: run a scenario — securities class action plus parallel derivative and SEC investigation — against the tower's order and Side C sublimits.
3. Buy standalone Side A excess if the company has material insolvency or non-indemnifiability scenarios.
4. Negotiate conduct exclusions at placement rather than accepting market manuscript forms; confirm the insured-versus-insured carve-backs cover derivative claims as brought.
5. Check indemnification agreements and bylaws against the policy: statutory advancement under Section 145(f) and contractual advancement must dovetail with coverage triggers, or gaps appear at the worst time.

Is D&O insurance a governance tool or just a cost?

Both, and the governance function is real: the quality of D&O terms is a factor in director recruitment, and insurers' underwriting questionnaires — asking about compliance programs, cyber posture, M&A processes — function as a private regulatory layer, with carriers declining or pricing for governance weaknesses. A board that cannot answer its own D&O questionnaire confidently has learned something useful about its program; the insurance market prices governance long before litigation does.